剂泰科技-P今日盘中大跌5.15%，引发了市场关注。
消息面上，剂泰科技作为全球AI药物递送第一股于近期登陆港交所，自上市首日大涨后已连续多个交易日回调，较首日高点回撤显著。公司尚处于商业化早期阶段，过去三年累计亏损约15亿元人民币，营收波动较大，业绩增长前景仍需时间验证。此外，部分国际配售股份未设置禁售期，上市后持续面临获利了结压力。尽管公司近日发布AiProtein平台及宣布与Deerfield达成战略联盟等利好，但新股上市初期市场热度加速消退，股价承压回落态势延续。
剂泰科技-P今日盘中大跌5.15%，引发了市场关注。
消息面上，剂泰科技作为全球AI药物递送第一股于近期登陆港交所，自上市首日大涨后已连续多个交易日回调，较首日高点回撤显著。公司尚处于商业化早期阶段，过去三年累计亏损约15亿元人民币，营收波动较大，业绩增长前景仍需时间验证。此外，部分国际配售股份未设置禁售期，上市后持续面临获利了结压力。尽管公司近日发布AiProtein平台及宣布与Deerfield达成战略联盟等利好，但新股上市初期市场热度加速消退，股价承压回落态势延续。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.